Pioneering the future: Delivering the first digitally generated CMC post-approval change dossier to global regulators...

As medicinal products and their manufacturing processes evolve, biopharmaceutical companies must continuously manage, document, and submit post-approval chemistry, manufacturing, and controls (CMC) changes to global health authorities. Traditionally, this process is time consuming, administratively burdensome, and hindered by region-specific requirements, often delaying the implementation of critical updates and improvements. In response, regulators and industry stakeholders are increasingly collaborating to enhance efficiency and expedite patient access to critical therapeutics. This article describes the initiation and organization of a pilot project focused on post-approval change (PAC) reliance/collaboration and digital authoring as part of an end-to-end process improvement initiative. The pilot aimed to demonstrate time savings in authoring, review, and approval by leveraging automation, cloud-based collaboration, and a common core CMC dossier. Of the target 37 National Regulatory Authorities (NRAs), 27 (73%) agreed to participate in the pilot, with 26 also utilizing a novel third-party collaboration platform. In this pilot, 85% (23/27) of participating NRAs reached approval within 9 months, compared with approximately 36 months typically required using a conventional post-approval submission process for comparable changes. These results underscore an emerging interest to embrace innovative regulatory practices and support the development of formal, scalable reliance/collaboration pathways.